Transcript Highlights:

• and psychedelic medicines, particularly psilocybin-containing mushrooms.
• In both Oregon and Colorado, regulated psilocybin programs already exist.
• If it wasn't for psilocybin therapy.
• I had my first therapeutic psilocybin experience.
• We make psilocybin therapy, legal, local unaffordable.

Bills: HF3454, HF3917, HF2906, HF3832, HF3769

Keywords: social work, licensure, employment titles, health occupations, professional standards, medication repository, drug donation, healthcare, Minnesota Statutes, pharmacy, public health, controlled substances, psilocybin, psilocin, psychedelic, psychedelic medicine, hallucinogen, mushrooms, magic mushrooms, therapeutic use

Transcript Highlights:

• When we talk about psilocybin therapy, we're not talking about the psilocybin that Chair Bliss may have
• When we talk about psilocybin therapy, we're not talking about the psilocybin that Chair Bliss may have
• psilocybin programs here in Minnesota. psilocybin programs here in Minnesota.
• first psilocybin therapy. first psilocybin therapy.
• use of psilocybin. use of psilocybin.

Bills: HF4588, HF3685, HF4577, HF4932

Keywords: veterans, veterans affairs, mental health, behavioral health, rural health, rural areas, access to care, task force, Minnesota Department of Veterans Affairs, general fund appropriation, veteran suicide prevention, PTSD, service members, military families, telehealth, rural psychiatry, high school diploma, armed forces, education policy, military service

Transcript Highlights:

• Psilocybin-assisted psychotherapy.
• Psilocybin programs already exist.
• Then in early 2021, I had my first therapeutic psilocybin experience.
• I had my first therapeutic psilocybin experience.
• We make psilocybin therapy, legal, local unaffordable.

Keywords: 1183, house

Transcript Highlights:

• . psilocybin. psilocybin.
• legalize psilocybin in New Hampshire. legalize psilocybin in New Hampshire.
• Um and so the psilocybin to use.
• <01:33:16.080> and across multiple trials psilocybin and across multiple trials psilocybin
• Until psilocybin is federal law.

Keywords: 1191, senate, all

Transcript Highlights:

• It included a number of different substances, some far less studied than psilocybin.
• LaFonte, who credits psilocybin with saving his life, to continue advocacy on this issue.
• LaFonte, who credits psilocybin with saving his life, to continue advocacy on this issue.
• On their website, they had a study done by Harvard that showed psilocybin could be helpful.
• And I can honestly say that psilocybin healed me both physically and mentally.

Keywords: 995, all

Summary: The Joint Committee on Revenue held a long hybrid hearing on a wide range of tax bills, with testimony covering cigarette and tobacco taxes, nicotine pouches, contractor rental equipment exemptions, aircraft sales tax exemptions, rolling stock, advanced sales tax payments, a gun and ammunition excise tax, a digital services tax, and a psilocybin cultivation/tax proposal. Committee chairs outlined the hearing process and noted that 39 House-filed sales and excise tax bills were being heard for required reporting by November 28. No votes were taken during the hearing. On tobacco-related bills, supporters including Senator Keenan, the American Heart Association, the American Cancer Society, and Tobacco Free Mass backed higher cigarette taxes and closing the synthetic nicotine loophole, arguing the measures would reduce youth initiation, encourage cessation, and offset health care costs. Retailers, wholesalers, and convenience-store groups opposed the increases, warning of smuggling, out-of-state purchasing, and harm to small businesses; premium cigar representatives argued cigars should be treated separately from cigarettes. The committee also heard testimony on H. 3067 and related bills concerning nicotine pouches, with public health advocates supporting taxation and industry witnesses urging a lower, more competitive rate. Several other bills drew sharply divided testimony. United Rentals supported H. 3065 to simplify contractor rental equipment exemption paperwork, while airport and aviation groups opposed bills to repeal the aircraft sales tax exemption, saying it would hurt airport competitiveness and jobs. The Transportation Association of Massachusetts backed rolling stock tax exemptions, saying the current tax discourages fleet investment and interstate commerce. Restaurant industry representatives supported repealing advanced sales tax payments and changing penalty rules, saying businesses were hit with retroactive penalties after unclear pandemic-era changes. On H. 3082, an excise tax on guns and ammunition, gun violence prevention advocates, Roca, and Giffords supported the bill as a dedicated funding source for prevention and survivor services, while sportsmen’s groups opposed it as unfair to lawful gun owners and harmful to conservation funding. The committee also heard testimony on H. 3208, a digital advertising services tax, with Representative Paulino supporting it as a way to capture revenue from online advertising and fund public needs, while the Chamber of Progress opposed it as costly and burdensome for small businesses and campaigns. Finally, multiple witnesses testified on H. 4050 regarding psilocybin cultivation and taxation: advocates from Mass Healing, Roca, the Reason Foundation, and individuals describing personal medical benefits urged a regulated, permit-based system, while the hearing ended after all signed-up speakers were heard and the chair adjourned the meeting.

Transcript Highlights:

• Psilocybin. Thank you. Go ahead. word? Psilocybin. Thank you. Go ahead.
• . psilocybin. psilocybin.
• So, schedule one is psilocybin bill. So, schedule one is psilocybin schedule<02:19:31.040> one.
• impossible to overdose on psilocybin. impossible to overdose on psilocybin.
• Um, are there convictions every year for use of psilocybin? Psilocybin. Silicon.

Keywords: 1191, senate, all

Transcript Highlights:

• I believe I'm alive today thanks to psilocybin therapy.
• H. 2203 would create a pathway for people to safely access psilocybin.
• In other words, psilocybin mushrooms allow me... ...that we take for granted.
• In other words, psilocybin mushrooms allow me. that we take for granted.
• Thanks. would want people to believe happens with psilocybin use.

Keywords: 995, all

Summary: The hearing opened with remarks from House Chair Mindy Domb and Senate Vice Chair Robyn Kennedy, who outlined procedures for the hybrid public hearing, noted the committee would hear testimony on 15 bills related to treatment settings, and recognized members present. The first major bill discussed was H. 4200, authorizing a pilot program for psychedelic-assisted treatment in licensed facilities. Representative Jim O’Day and witnesses from Control Z supported the bill, describing it as a tightly controlled, medically supervised pilot with DPH oversight, limited sites, and screening requirements. Committee members asked about the number of sites and whether Column Health still existed; witnesses said the bill contemplated three separate pilot programs and that Column Health no longer existed after being purchased by another company. The committee also heard testimony on S. 1405 to make the drug stewardship program permanent by removing its 2026 sunset date. Senator John Keenan and others said the program helps collect and safely dispose of unused medications, reduces diversion, and should remain in place because manufacturers should bear disposal costs. A member from Boston added support based on local concerns about people searching through bags for drugs, and Keenan explained the original sunset reflected pilot status and industry pushback. A large portion of the hearing focused on S. 1394 and H. 2193, which would strengthen implementation of the 2023 Roadmap for Behavioral Health Reform. The Children’s Mental Health Campaign, Parent/Professional Advocacy League, Massachusetts Association for Mental Health, and Elliott Community Human Services testified that the roadmap’s helpline, community behavioral health centers, and crisis services are important but unevenly implemented. They urged a single point of accountability within EOHHS, regular strategic planning, a public data dashboard, and financial analysis of the behavioral health system and the access and crisis intervention trust fund. Witnesses said commercial insurance often does not fully reimburse community behavioral health center services, making sustainability difficult, and asked for better coordination across agencies and crisis response systems. Committee members asked whether the roadmap includes substance use disorder; witnesses said it is intended to cover behavioral health broadly, including mental health and substance use. The committee also heard testimony on bills to ban aversives and on suicide prevention signage. Lisa Jean Graff testified in support of S. 1394 by urging a statewide ban on aversive practices, including electric shock, withholding food or bathroom access, and other painful interventions, arguing disabled people deserve the same protections from harm as others. Fonda Bryant and Carol McLean supported a bill requiring suicide prevention signs on tall parking garages, describing personal experiences and saying the signs could create a brief pause and connect people to 988 or other help. McLean said her son died by suicide from a parking garage and that signage might have made a difference. The committee also heard strong testimony in support of creating intensive stabilization and treatment units within DMH facilities (S. 1398/H. 2204), with the Massachusetts Nurses Association and a DMH nurse arguing that highly assaultive patients need specialized, more secure units to protect staff and other patients and to improve care. Additional testimony supported creating a dedicated board for licensed mental health counselors (H. 4696/S. 1382), with Rep. John Badger, the Mass Mental Health Counselors Association, and others saying LMHCs are a large and growing workforce that needs its own licensing board, clearer standards, and faster implementation of existing licensure reforms. The committee also heard extensive testimony on H. 2223 regarding benzodiazepines and non-benzodiazepine hypnotics. Survivors and advocates described severe withdrawal, lack of informed consent, cognitive harms, and long-term disability, while a physician supported the bill as a way to improve disclosure of risks. Finally, the committee heard multiple witnesses in favor of H. 2231/S. 1383 to establish peer-run respite centers statewide. Advocates and people with lived experience said peer respites provide non-coercive, home-like alternatives to hospitalization, can reduce trauma and repeated admissions, and may be especially important for marginalized communities; they also cited cost savings and existing positive outcomes from current respite programs. No votes or final committee actions were taken during the hearing portion reflected in the transcript.

Transcript Highlights:

• Yes, when you think about, like, let’s say psilocybin, for example, right?
• So, like, there is natural psilocybin and then there’s synthetic versions of psilocybin. ...and what
• and then a synthetic form of psilocybin.
• So, yes, we could think about, you know, the use of natural psilocybin.
• We could also think about the use of synthetic psilocybin.

Keywords: 1182, all

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies met to discuss psychedelic-assisted treatments for serious mental health conditions, with a focus on psilocybin, ibogaine, MDMA, and related compounds. The chair framed the issue as a clinical and access problem for veterans, first responders, and others with PTSD, depression, TBI, addiction, and suicidal ideation, emphasizing that these therapies are intended for supervised medical settings rather than take-home use. Members reviewed research claims and policy trends, including FDA breakthrough therapy designations, state-level psychedelic legislation, and the role of Arizona’s right-to-try law in expanding access once federal approval is in place. Testimony came from Alan Mullen, a retired Army Special Forces veteran, who described his PTSD/TBI history and said ibogaine treatment helped him confront trauma and showed promise in reducing symptoms under strict medical monitoring. Dr. Sue Cisley of Scottsdale Research Institute described ongoing FDA-controlled trials in Arizona, said current medications often fail high-need patients, and urged removal of research barriers and preparation for right-to-try and expanded access. Dan Freiberg of the Professional Firefighters of Arizona said firefighters face chronic exposure to trauma, often rely on alcohol or other coping mechanisms, and need effective alternatives beyond traditional therapy. Dr. Chung Trin discussed late-stage psychedelic trials, the FDA breakthrough pathway, safety oversight, and the need for state readiness when approvals occur. Committee members asked about how the treatments work, whether they require psychotherapy support, safety concerns including suicidality and black-market abuse, patenting and synthetic versus natural versions, and costs compared with ketamine and other treatments. Witnesses said the therapies are administered with extensive screening, monitoring, and integration support, and argued that addiction potential appears low under medical supervision. The discussion ended with interest in sending correspondence to federal officials to support right-to-try cooperation and in continuing the research and policy work; no formal vote or action was taken in the portion provided.

Transcript Highlights:

• Psilocybin was extremely helpful to me as a patient.
• This bill does not legalize psilocybin broadly.
• Classifying psilocybin as Schedule I is fraudulent.
• Classifying psilocybin as Schedule I is fraudulent.
• I am testifying in support of H. 2506 to decriminalize psilocybin.

Keywords: 995, all

Summary: The committee heard testimony on a wide range of public health and emergency services bills, with many speakers focusing on EMS system failures, hospital service closures, trauma preparedness, epilepsy awareness, drink-spiking response, sudden cardiac arrest, and survivor financial assistance. Several legislators and advocates described the EMS system as underfunded and overstretched, citing long ambulance waits, staffing shortages, and the need for statewide oversight, a special commission, and clearer recognition of EMS as an essential service. A number of speakers also supported bills to preserve essential hospital services after closures such as Nashoba Valley Medical Center and birthing services in Leominster, arguing that current closure rules lack enforcement and leave communities without critical care. Multiple panels testified in support of bills requiring trauma kits in public buildings, public education on SUDEP and epilepsy mortality, and improved cardiac arrest response. Supporters of the trauma-kit bill said public buildings should have bleeding-control kits and trained staff, comparing them to AEDs and first aid supplies. Epilepsy advocates, clinicians, and grieving parents urged a public health campaign on SUDEP, saying families are often not warned about the risk and that awareness could improve medication adherence, reduce guilt, and save lives. On cardiac arrest, EMS professionals and the American Heart Association backed measures to improve telecommunicator CPR, create an AED registry, and strengthen dispatch and training standards. The committee also heard extensive testimony on a bill addressing illicit drink spiking. Senators, city officials, victims, physicians, and an international anti-spiking advocate described cases in which hospitals refused toxicology testing unless a sexual assault was reported, and argued for standardized testing protocols, better data collection, and coordination with law enforcement and licensed venues. Another bill drew a sharp exchange over local public health control and the SAFE 2.0 law, with one senator arguing for more local approval and voluntary participation, while committee members defended the earlier law as a response to inequities in local public health capacity. Finally, advocates from Jane Doe, Inc. supported legislation to provide flexible financial assistance to survivors of domestic and sexual violence, saying unrestricted cash helps survivors meet basic needs, escape abuse, and rebuild stability.

Keywords: 1189, house, all

Transcript Highlights:

• Uh this is one of three psilocybin.
• > it<02:09:22.480> is background on psilocybin, it is background on psilocybin, it is naturally
• :48.960> promise Psilocybin is showing incredible promise Psilocybin is showing incredible promise
• :10:02.000> already accessing psilocybin mushrooms already accessing psilocybin mushrooms already
• 27.119> used Psilocybin mushrooms are widely used Psilocybin mushrooms are widely used among<02

Keywords: 1187, senate, all

Transcript Highlights:

• Why are cannabis and alcohol accepted, but psilocybin isn't?
• Why are cannabis and alcohol accepted, but psilocybin isn't?
• I can honestly say that psilocybin healed me both physically and mentally.
• I urge the Joint Committee to make psilocybin legal access a legal option.
• Psilocybin has not been found, either in Psilocybin has not been found, either in the communities here

Keywords: 995, all

Summary: The committee opened with procedural guidance for a very large hearing, explaining testimony limits, written testimony procedures, and rules for maintaining order. Members then heard testimony on a wide range of bills, including proposals to define antisemitism using the IHRA definition, regulate facial recognition technology, restrict weaponized robotics and drone use, expand protections for journalists’ confidential sources, address access to decedents’ email accounts, and create or adjust rules around municipal enforcement and animal cruelty fines. Several sponsors and advocates asked for favorable reports, and committee members asked clarifying questions on implementation, costs, and how the bills would interact with existing law. On facial recognition, sponsors and advocates described the technology as a threat to privacy, due process, and civil liberties, and urged adoption of the Special Commission’s recommendations, including warrant requirements, notice to defendants, and limits on untargeted surveillance. Support came from legislators, the ACLU, CDT, EFF, and a UMass professor, while committee members asked about current state law and municipal bans. On robotics, Senator Moore and industry witnesses from MassRobotics, Boston Dynamics, and AUVSI supported a bill prohibiting weaponized robots and requiring warrants for certain law enforcement uses, describing it as a public-safety and trust-building measure. On the shield law bill, newspaper publishers, journalists, NEFAC, and the Reporters Committee argued Massachusetts needs statutory protection for confidential sources, citing costly subpoenas and chilling effects on reporting. The committee also heard testimony on a bill to expand the right of publicity to cover image and voice, with SAG-AFTRA members supporting protections against AI-driven exploitation and some discussion about viral content and consent. Another bill would allow limited access to a decedent’s email accounts, with one witness describing a family’s inability to use a deceased relative’s email to notify friends. The committee then took testimony on psilocybin-related bills: supporters described medical and personal benefits and argued for narrow decriminalization or study, while an opponent warned of public-health risks, impaired driving, and youth exposure; the Massachusetts Psychiatric Society supported limited, safety-based decriminalization. Finally, the committee heard strong support for a “safe reporting” bill for sex workers and trafficking survivors, with advocates saying immunity would encourage victims and witnesses to report crimes without fear of arrest, and members raised questions about how the immunity would work in practice.

Transcript Highlights:

• FDA-designated breakthrough therapies, including MDMA and psilocybin-assisted treatments, have shown
• I have led multiple trials on novel therapies like MDMA and psilocybin, which have been designated by
• FDA-designated breakthrough therapies, including MDMA and psilocybin-assisted treatments, have shown
• <00:43:00.000> assisted including MDMA and psilocybin assisted including MDMA and psilocybin
• I have led multiple trials on novel therapies like MDMA and psilocybin, which have been designated by

Keywords: 912, senate, all

Summary: The Health and Human Services Committee heard testimony on several measures related to child welfare, health care access, overdose response, disability services, and waste management. For SB 710 on child welfare, the Department of Human Services, the Office of Wellness and Resilience, the Attorney General’s office, and multiple advocacy groups testified in support, with the Governor’s office noting support but deferring to the Attorney General on implementation because of separation-of-powers concerns. For SB 952 on child welfare services, DHS, the Governor’s office, and child- and trauma-informed care advocates supported the bill, saying it would help families access services, provide basic material support, and reduce strain on the child welfare system. SB 954 on a home health services rate study also drew support, including from DHS, the Hawaii Healthcare Association, and a public testifier who said the study would help ensure funds reach low-income, disabled, and kupuna recipients. SB 957 on overdose prevention received support from the Department of Health and the Attorney General, who said overdose prevention centers are evidence-based but raised federal-law concerns and recommended amendments; the Hawaii Health and Harm Reduction Center and others also testified in support. The committee then moved to the 1:00 regular calendar and heard SB 850 on disability health disparity, which was supported by the Executive Office on Aging, the Hawaii State Council on Developmental Disabilities, the Hawaii Disability Rights Center, self-advocates, and others. Testimony emphasized that a disparity study could improve workforce development, training, and services for people with disabilities. SB 838 on continuous glucose monitoring drew support from health agencies and advocates, with testimony stressing that monitors can be critical for some diabetes patients. SB 829 on health care was supported by the Department of Health and health care stakeholders, who said it would help rotating physicians serve neighbor islands without local hospital privileges and align with CMS rules. SB 446 on waste management drew mixed testimony: the Department of Health and several public entities provided comments, the County of Maui opposed, and environmental advocates urged stronger aquifer protections and limits on ash reuse. During decision making, the committee adopted recommendations to pass SB 298, SB 322, SB 299, SB 450, SB 451, SB 949, SB 710, SB 957, SB 69, and SD 952 with various amendments, including technical changes, blank appropriations, and defective dates. SB 323, SB 324, SB 712, SB 950, SB 954, and SB 959 were deferred, largely because companion House measures were moving or similar Senate measures had already passed. The chair also announced recesses to find quorum and noted that some bills from the earlier Monday calendar were being deferred to avoid duplication.

Transcript Highlights:

• “Yeah, so the bill was written for psilocybin, so it would be in the bill that psilocybin would be the
• It is specifically only allowing pilot programs to leverage psilocybin. Thank you.
• Senator Talents, is psilocybin approved by the FDA? No, it is a Schedule I. Thank you.
• And psilocybin specifically doesn't.
• If you use a big dose of psilocybin today, that's what we advocate.

Keywords: 995, all

Summary: The Joint Committee on Mental Health, Substance Use and Recovery opened its first public hearing of the 2025–26 session with remarks from the Senate and House chairs outlining the committee’s priorities. They noted recent work on addiction and recovery legislation, the ongoing youth behavioral health crisis, and that members might need to leave periodically for floor votes. The chairs explained hearing procedures, including three-minute testimony limits, written testimony deadlines, and reporting deadlines for Senate and House bills. The hearing then focused on several bills related to youth mental health, overdose prevention, and psychedelic treatment research. A major portion of the hearing centered on bills to improve youth crisis response and overdose prevention. Testimony strongly supported bills to print the 988 Suicide and Crisis Lifeline on student ID cards, with speakers from mental health organizations, crisis centers, and individuals sharing personal stories of depression, suicide attempts, and the importance of making 988 as familiar as 911. Another set of bills would require schools to stock naloxone and provide overdose prevention education. Physicians, harm reduction advocates, students, and grieving family members testified that school-based Narcan access and education could save lives, reduce stigma, and help students recognize overdoses and understand Good Samaritan protections. Senator O’Connor and Tamika Perry also testified for a bill to strengthen substance use prevention education and reduce overdose abandonment, emphasizing the need to teach students about overdose risks and the legal protections for calling 911. The committee also heard testimony on a bill to authorize a pilot program for psychedelic treatment in licensed facilities. Senator Friedman and several medical and behavioral health professionals argued the proposal was a narrow, research-based approach distinct from the broader ballot question rejected in 2024. They said the bill would allow only a small number of supervised clinics to use psychedelics for conditions such as depression, PTSD, anxiety, and substance use disorders, with data reporting and Department of Public Health oversight. Supporters described it as a cautious way to study promising treatments while avoiding unsupervised or commercialized use. Finally, the committee heard support for a bill to create a special commission and five-year strategic plan for children’s behavioral health services, with testimony that the current system is fragmented, difficult for families to navigate, and strained by workforce and funding challenges. No votes or final actions were taken during the hearing; the committee primarily received testimony and questions on the bills.

Transcript Highlights:

• At this time, I have an act relative to therapeutic psilocybin treatment centers.
• 100% disabled, and he credits psilocybin with not only saving his life, but allowing him to complete
• A growing body of research shows that psilocybin can be a safe and effective treatment for a number of
• Psilocybin, when administered within the carefully structured trauma-informed model this bill aims to
• Psilocybin, when administered within the carefully structured trauma-informed model this bill aims to

Keywords: 995, all

Summary: The committee hearing covered a wide range of public health bills, with much of the testimony focused on two major themes: expanding access to care and stabilizing health-related workforces and services. On House 2364, an act relative to medical health and fitness facilities, representatives from Dedham Health and Athletic Club argued for a pilot program recognizing supervised exercise as medicine, saying it could improve outcomes for chronic disease, fall prevention, and mental health while reducing costs. On House/Senate bills concerning community health workers (H. 359/S. 251), multiple witnesses from MACHW, Health Care for All, MHA, Cambridge Health Alliance, Mass General Brigham, Boston Children’s Hospital, Asian Women for Health, and the City of Somerville described CHWs as essential for navigation, trust-building, language access, and addressing social needs, and urged reimbursement by MassHealth, the GIC, and private insurers, along with workforce development measures. One pediatric neurologist also told the committee that losing grant-funded CHW support led to more avoidable ER visits and threatened clinic operations. The committee also heard extensive testimony on hospital closures and essential services. Witnesses including Dr. Alan Sager, MNA President Katie Murphy, nurses from Brockton Hospital and Providence Behavioral Health, and local officials and legislators from Norwood described the loss of hospitals and service lines, especially maternity, pediatric, and behavioral health care, and argued current closure processes are too weak to protect communities. They supported bills such as H. 2460/S. 1503 and H. 2534/S. 1574, which would require earlier notice, community input, stronger state oversight, possible receivership, and limits on reopening or expanding after closures. Testimony emphasized the impact of Steward’s bankruptcy, the closures of Carney and Neshoba Valley, and the need to preserve access to essential services in underserved areas. Several end-of-life and professional regulation bills were also discussed. On H. 2436, Representative Omar Gomez and funeral industry witnesses supported eliminating Office of the Chief Medical Examiner fees for the removal of a child’s body in cases involving children five and under, describing the bill as a small but important relief for grieving families. On H. 2444 and related Senate bills, cemetery and consumer advocates supported legalizing alkaline hydrolysis and natural organic reduction as environmentally friendly after-death options, while cemetery representatives opposed H. 2360, which would allow funeral establishments to operate crematories, arguing cemeteries should retain that role. The committee also heard support for H. 2382, which would exempt dentists and oral surgeons from a new office-based surgical center framework, and for H. 2461, which would create hospital efficiency standards; employers and retailers backed that bill as a way to address rising health care costs. Finally, the committee heard testimony on autism services and hospital governance. On S. 1414, behavior analysts and school representatives said Massachusetts already licenses assistant-level ABA providers but MassHealth does not reimburse them, causing long waitlists and limiting school and family access; an actuary testified that a three-tier ABA reimbursement model could reduce MassHealth costs by up to 6% per child served. Senator Lovely also testified in support of S. 1572, which would require at least one registered nurse on each acute care hospital governing board, arguing nurses’ frontline perspective would improve quality and retention. No votes were taken in the hearing excerpt, but many witnesses urged favorable reports on their respective bills.

Transcript Highlights:

• Psilocybin<00:04:39.040> demonstrates<00:04:39.600> efficacy<00:04:40.080> for Psilocybin
• But I had to fly to a state where psilocybin is legally regulated.
• But I had to fly to a state where psilocybin is legally regulated.
• <00:12:32.639> build of serving on Hawaii psilocybin build of serving on Hawaii psilocybin
• There's ibogaine, there's MDMA, there's ketamine, there's psilocybin, there's different things.

Keywords: 912, senate, all

Summary: The committee heard testimony on SB 3025, relating to medical debt, with multiple organizations and individuals, including the Office of Wellness and Resilience, Healthcare Association of Hawaii, Queens Health Systems, the American Cancer Society Cancer Action Network, Aloha Care, Hawaii Health and Harm Reduction, Hawaii Data Collaborative, and Hawaii Appleseed, all speaking in support. No opposition was heard, and the member present had no questions. The committee then took up SB 3199, which would establish a mental health emerging therapies task force. Testimony was overwhelmingly in support, with speakers including veterans, clinicians, researchers, and advocacy groups describing personal experiences with PTSD, depression, traumatic brain injury, and treatment-resistant conditions, and arguing that Hawaii should prepare for regulated access to emerging therapies such as MDMA, psilocybin, ketamine, and ibogaine. The Department of Health and some medical organizations provided comments, and one opposition witness was called but not present. The chair noted broad support, especially from veterans, and no vote was taken during the excerpt. The final measure discussed was SB 3324, relating to Medicaid. The Department of Human Services, Department of Health, Hawaii State Council on Developmental Disabilities, Hawaii Disability Rights Center, Aloha Care, and numerous care-provider and aging/disability organizations testified in support, while one witness was in opposition and several others offered comments. The discussion then moved to SB 2563, relating to homelessness, where the Department of the Attorney General offered comments on specific sections and recommended adopting suggested amendments if the bill proceeds. Additional testimony on SB 2563 began with support from several individuals, including Shelby Pikachu, who emphasized the severity of homelessness and related social problems in the community.

Transcript Highlights:

• Um, psilocybin is a, um, chemical derivative of, um, I would say mushroom compounds.
• <00:05:12.680> Um<00:05:12.880> psilocybin the Senate. Um psilocybin the Senate.
• Um psilocybin is<00:05:15.840> a<00:05:16.560> um is a um is a um chemical<00:05:19.040

Keywords: Drug Policy - Room 409, 26 February, 2026; 2:30 P.M., 925, all

Summary: The Senate Drug Policy Committee met to consider two bills. For House Bill 417, which updates the Uniform Controlled Substances Act by adding substances to Schedule I, committee counsel explained that a strike-all was needed because the House version relied on outdated correspondence. Anna Catherine Lambert of the Mississippi State Department of Health said the department updates the language each year by matching Mississippi law to the DEA’s Federal Register, including salts, isomers, and related forms of newly scheduled substances. She noted the additions largely fall into three broad categories, including fentanyl derivatives, phenidates, and tazenes. Senators asked about the number of compounds and the need to list each derivative form. The committee moved to adopt the strike-all and then the title sufficient do pass strike-all, and the bill was reported. The committee then took up House Bill 563, which would allow Mississippi law to conform automatically if psilocybin is scheduled by the federal government before the next legislative session. The chair described psilocybin as a mushroom-derived compound being studied in clinical trials for treatment-resistant depression, and noted that an email from Veterans Exploring Treatment Options supported the legislation. Members discussed that the bill would prevent delay if federal scheduling occurs and asked about the conditions for which the substance might be used; the response mentioned treatment-resistant depression, traumatic brain injury, substance use disorder, and other mental health indications. Senator Blackmon made a lighthearted comment about possible amendments, but no amendments were adopted. The committee approved the motion for title sufficient to pass, and House Bill 563 was reported.

Transcript Highlights:

• House amended and passed Senate Bill 906, permitting lawful prescription of crystalline polymorph psilocybin
• Senate Bill 906, permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
• The House added the drug that contains organic psilocybin substance that has received U.S.
• President, the House added the drug that contains organic psilocybin substance that has received U.S.

Keywords: 994, senate, all

Summary: The Senate first considered confirmations from Senate Executive Message No. 4. On a 33-0 vote, it confirmed all nominees except number 54, then separately confirmed nominee 54 on a 30-3 vote. The special order of business was then closed. The chamber then took up a series of House-amended bills and generally concurred in the amendments before passing each bill. These included SB 723 on law enforcement cooperation with bordering states; SB 947 on birth certificate copies for homeless minors; SB 392 on personal income tax reduction; SB 54 on criminal penalties for abuse or neglect of incapacitated adults; SB 228 on technology in child abuse and neglect investigations, including a three-county caseworker aid pilot; SB 231 on value-based payment requirements; SB 402, the Workforce Readiness Opportunity Act, with House removal of tax credits and other provisions while retaining micro-credential programs; SB 553 on transfer of contractor licenses to qualifying immediate family members; SB 575 on refusal review hearings; SB 686, the Coal Tenancy Modernization and Miners' Protection Act; SB 906 on lawful prescription of crystalline polymorph psilocybin under FDA recommendations; and SB 1226 on penalties for disturbing religious worship. Most final passage votes were unanimous or near-unanimous, and several bills were made effective from passage or given a specific effective date. Later, the Senate concurred in House amendments to SB 63, the Creating Sustaining Opportunities for Academics and Rural Schools Act, after discussion noting the House removed county charter school language and changed the effective date. The bill passed 32-2 and was made effective from passage. The Senate also concurred in amendments to SB 502, the Women's Collegiate Sports Protection Act, and SB 153, creating the Unemployment Automation and Administration Fund; SB 502 was set to take effect July 1, 2026, and SB 153 was also made effective July 1, 2026. Finally, the Senate reconsidered and again passed SB 392 by a 32-2 vote. The session ended with several introductions, announcements, and a recess until 5:30.

Transcript Highlights:

• interventions these psilocybin interventions these psilocybin especially<01:05:34.480> has
• <01:05:59.119> trial<01:05:59.480> for that funds A psilocybin trial for that funds
• A psilocybin trial for veterans<01:06:00.079> with<01:06:00.440> PTSD<01:06:01.440>
• So virtually no patients have access to psilocybin or MDMA until approval.
• country have received MDMA or psilocybin country have received MDMA or psilocybin through<01:41:

Keywords: 910, house, all

Transcript Highlights:

• Psilocybin has multiple uses: end-of-life, trauma, etc.
• And he did answer back to me, quote, "Psilocybin in preliminary studies from Johns Hopkins are looking
• There are now three centers of NIH starting to study the use of psilocybin as a treatment for nicotine
• Earlier, I brought up the potential initial use of psilocybin in quitting.
• Psilocybin is a plant-based medicine. This plant-based medicine is called Ivocaine.